Show simple item record

Targeting the PI3K/Akt/mTOR pathway : A therapeutic strategy in COVID-19 patients  

dc.contributor.authorAbu Eid, Rasha
dc.contributor.authorWard, Frank James
dc.date.accessioned2022-10-19T23:07:42Z
dc.date.available2022-10-19T23:07:42Z
dc.date.issued2021-12
dc.identifier200423798
dc.identifierbf2b5a0c-bd26-45d8-b22f-7ca66aff1daf
dc.identifier85115975872
dc.identifier.citationAbu Eid , R & Ward , F J 2021 , ' Targeting the PI3K/Akt/mTOR pathway : A therapeutic strategy in COVID-19 patients   ' , Immunology Letters , vol. 240 , pp. 1-8 . https://doi.org/10.1016/j.imlet.2021.09.005en
dc.identifier.issn0165-2478
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/19216
dc.descriptionFunding This work was supported by Friends of ANCHOR pilot research award [grant number RS 2019 004, 2020-2021]en
dc.format.extent8
dc.format.extent652868
dc.language.isoeng
dc.relation.ispartofImmunology Lettersen
dc.subjectCOVID-19en
dc.subjectPI3Ken
dc.subjectAkten
dc.subjectmTORen
dc.subjectImmune modulationen
dc.subjectThrombosisen
dc.subjectRK Dentistryen
dc.subjectOtheren
dc.subjectRS 2019 004en
dc.subject2020-2021en
dc.subject.lccRKen
dc.titleTargeting the PI3K/Akt/mTOR pathway : A therapeutic strategy in COVID-19 patients  en
dc.typeJournal itemen
dc.contributor.institutionUniversity of Aberdeen.Dental Educationen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1016/j.imlet.2021.09.005
dc.date.embargoedUntil2022-09-23
dc.identifier.vol240en


Files in this item

Thumbnail
Name:
Archbold_etal_IMRN_Local_Varia ...
Size:
399.7Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record